



## **Singapore government investment arm of SPRING SEEDS Capital backs Trendlines Medical Singapore and Ozi Amanat's K2 Global to collaborate in its SGD100M investment allocation for tech start-ups**

Misgav, Israel – Singapore – 8 February 2018 – The Trendlines Group Ltd. ("Trendlines") (SGX: 42T, OTCQX: TRNLY), an Israeli company focused on developing innovation-based medical and agricultural companies, announced that its subsidiary, Trendlines Medical Singapore Pte. Ltd. ("Trendlines Medical Singapore") will collaborate with Ozi Amanat's Singapore-based venture capital firm K2 Global Pte Ltd ("K2 Global") and has been appointed as one of the partners under the Startup SG Equity scheme, administered by SPRING SEEDS Capital Pte. Ltd. ("SSC"). In July 2017, SSC announced a SGD100 million investment allocation to groom start-ups and issued a call to the appointed partners to co-invest in the health and biomedical sciences and other fields.

Together, Trendlines Medical Singapore and K2 Global will invest in medical technology companies seeking Series A funding. Trendlines Medical Singapore CEO Eric Loh remarked, "The collaboration between Trendlines Medical Singapore and K2 Global leverages Trendlines' experience and proven track record in identifying, incubating, and grooming medical technology companies while working closely with K2 Global to provide growth capital and support to help scale operations and facilitate global opportunities. This is an ideal relationship that will contribute substantial value to Singapore's medical technology start-up ecosystem."

Founder of K2 Global Ozi Amanat added, "As a venture capital firm, K2 Global has had great successes in harnessing the value of growth-stage companies. The partnership with Trendlines Medical Singapore combines the strength of our two companies and adds tremendous value to medical technology companies seeking continuous business nurturing while exposing themselves to the plethora of opportunities in global markets."

Trendlines Medical Singapore and K2 Global anticipate co-investing with SCC in more than 11 companies during the eight-year period of the partnership and consider the pipeline of

deals originating from Trendlines Medical Singapore's incubator, and other companies that have a strong development focus in Singapore, as a rich environment for investment.

Chairman of Trendlines Medical Singapore Todd Dollinger added, "We are pleased to work together with SPRING SEEDS Capital in translating healthcare and biomedical technology — through active incubation and follow-on financing — into growing companies that will improve the human condition. Our participation in the Startup SG Equity program broadens our ability to develop early-stage medical technology companies in Singapore. Our collaboration with K2 Global will further strengthen our successful efforts in raising funds from strategic investors to boost the value of our portfolio companies. We expect numerous successful investment outcomes in the coming years."

Chairman of SPRING SEEDS Capital and Deputy Chief Executive of SPRING Singapore, Ted Tan said, "The Trendlines Group has a good track record in Israel, with its portfolio of companies having raised significant follow-on funding and achieved sizeable exits. Their partnership with K2 Global will provide access to new networks and capital, which will boost the deep tech scene in Singapore. We look forward to partnering with Trendlines Medical-K2 Global in advancing medical technology development, a key area under the Research, Innovation and Enterprise 2020 masterplan."

The entry into the collaboration with K2 Global by Trendlines Medical Singapore is not expected to have any material impact on the earnings per share and net tangible asset per share of The Trendlines Group for the financial year ending 31 December 2018.

The Company will update shareholders via SGXNET if and when there are any further material developments in connection with the partnership with K2 Global.

None of the Company's directors, substantial shareholders, and/or any of their respective associates has any interest, direct or indirect (other than through their shareholdings in the Company), in the above partnership.

#### **About Trendlines Medical Singapore Pte. Ltd.**

Trendlines Medical Singapore ([www.trendlines.com/trendlines-medical-singapore/](http://www.trendlines.com/trendlines-medical-singapore/)) is a medical technology start-up incubator established by Trendlines and B. Braun Melsungen AG, one of the world's leading medical device companies. Trendlines Medical Singapore discovers, invests in, incubates, and provides a range of services to nurture and develop

Singapore-based companies involved in novel medical devices and technologies with a view toward success in the global market.

#### **About The Trendlines Group Ltd.**

Trendlines ([www.trendlines.com](http://www.trendlines.com)) is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfil its mission to improve the human condition. An intensely hands-on investor, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX (OTCQX: TRNLY).

#### **About K2 Global Pte. Ltd.**

K2 Global (<http://www.k2globalvc.com/>) was founded by Singapore venture capitalist Ozi Amanat. A prominent investor known for investing in a number of unicorns (Spotify, Magic Leap, Paytm, Uber, Palantir, Airbnb) and in Alibaba and Twitter before their public offerings. With over SGD250 million in committed capital, Ozi and K2 Global are among Singapore's largest venture investors.

#### **About SPRING SEEDS CAPITAL Pte. Ltd.**

SPRING SEEDS Capital (SSC), the investment arm of SPRING Singapore, co-invests with independent investor(s) in high potential Singapore-based startups with innovative and strong intellectual content that are scalable across international markets. It also manages co-investment funds administered under Startup SG Equity, a scheme which catalyzes private-sector investment for startups through government equity co-investment. Under Startup SG Equity, SSC supports early-stage startups across a wide range of technology and industry domain areas. For more information on the funding programs, please visit [www.spring.gov.sg](http://www.spring.gov.sg) and [www.startupsg.net](http://www.startupsg.net).

#### **About Startup SG**

Startup SG represents the shared interests of the startup community and positions Singapore as a leading startup hub. It provides entrepreneurs with a launch pad and a platform to connect them to the global stage, and access to local support initiatives. Please visit [www.startupsg.net](http://www.startupsg.net) for more information and news.

For more information on the SSC funding programs, visit [www.startupsg.net](http://www.startupsg.net).

-----

This press release has been prepared by The Trendlines Group Ltd. (the “Company”) and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”) for compliance with the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Jennifer Tan, Senior Manager, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: [sponsorship@ppcf.com.sg](mailto:sponsorship@ppcf.com.sg))

#### **Investor Contact Information**

##### **Israel**

Shira Zimmerman, The Trendlines Group

[shira@trendlines.com](mailto:shira@trendlines.com)

Tel: +972.72.260.7000

##### **Singapore**

Reyna MEI, Financial PR

[reyna@financialpr.com.sg](mailto:reyna@financialpr.com.sg)

Tel: +65.6438.2990